Medicine and Dentistry
Amphotericin B
10%
Antifungal Agent
9%
Antifungal Therapy
12%
Apoplexy
18%
Autoimmune Disease
7%
Biological Product
7%
Biological Therapy
17%
Bloodstream Infection
8%
Central Nervous System
9%
Clinical Feature
10%
Clinical Management
7%
Clinician
10%
Coccidioidomycosis
7%
Cohort Effect
34%
COVID-19
28%
Cryptococcal Meningitis
12%
Cryptococcosis
20%
Diagnosis
10%
Disease
37%
Disseminated Herpes Zoster
21%
Endocarditis
18%
Fluconazole
11%
Histoplasmosis
15%
Human Immunodeficiency Virus
32%
Immunocompromised Patient
25%
Immunosuppressive Treatment
8%
Infection
93%
Infective Endocarditis
29%
Inflammatory Disorder
9%
Intensive Care Unit
9%
Invasive Aspergillosis
15%
Itraconazole
7%
Kidney Graft
8%
Liver Graft
6%
Mucormycosis
7%
Mycosis
44%
Observational Study
7%
Opportunistic Infection
11%
Pathogen
9%
Prospective Cohort Study
11%
Race Difference
8%
Rheumatoid Arthritis
16%
Sepsis
14%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Silo-Filler's Disease
7%
Solid Organ Transplantation
12%
Surgery
9%
Systemic Mycosis
25%
Transplantation
52%
Tumor Necrosis Factor
7%
Keyphrases
AIDS/HIV
19%
Amphotericin B
14%
Anti-tumor Necrosis Factor Therapy
19%
Antifungal Susceptibility
10%
Antifungal Therapy
12%
Autoimmune Disease
17%
Biologic Therapy
12%
Candidemia
16%
Clinical Features
12%
Clinical Outcomes
14%
Clinical Presentation
10%
Confidence Interval
31%
COVID-19
25%
Cryptococcal Meningitis
15%
Cryptococcosis
18%
Cryptococcus Neoformans
12%
Disease-modifying Antirheumatic Drugs (DMARDs)
10%
Epidemiology
37%
Fluconazole
22%
Fungal Infection
28%
Geographical Differences
13%
Herpes Zoster
17%
Histoplasmosis
35%
Hospital-acquired Infection
10%
Immunocompromised Patients
13%
Incidence Rate
12%
Infection Rate
10%
Infectious Diseases
13%
Infective Endocarditis
21%
Inflammatory Diseases
11%
Invasive Aspergillosis
12%
Invasive Candidiasis
12%
Invasive Fungal Disease
16%
Invasive Fungal Infection
22%
Itraconazole
10%
Non-biologic
12%
Opportunistic Infections
11%
Posttransplant Infection
10%
Racial Differences
13%
Rheumatoid Arthritis
28%
Rheumatoid Arthritis Patients
10%
Risk Factors
13%
Sepsis
21%
Solid Organ Transplant
12%
Solid Organ Transplant Recipients
40%
Solid Organ Transplantation
12%
Systemic Juvenile Idiopathic Arthritis (sJIA)
11%
Transplant Recipients
24%
Transplantation
11%
United States
15%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
6%
Amphotericin B
11%
Antifungal Agent
20%
Antifungal Therapy
17%
Aspergillosis
6%
Aspergillus
8%
Autoimmune Disease
16%
Bacteremia
8%
Bacterial Endocarditis
20%
Biological Product
26%
Bloodstream Infection
8%
Candida
14%
Candidemia
10%
Candidiasis
8%
Cohort Study
10%
Cryptococcal Meningitis
7%
Disease
40%
Disease Modifying Antirheumatic Drug
10%
Endocarditis
11%
Etanercept
7%
Fluconazole
13%
Herpes Zoster
21%
Histoplasma
6%
Histoplasmosis
27%
HIV
24%
Immunocompromised Patient
12%
Infection
100%
Infectious Agent
9%
Inflammatory Disease
10%
Invasive Aspergillosis
10%
Invasive Candidiasis
12%
Itraconazole
9%
Juvenile Rheumatoid Arthritis
8%
Malignant Neoplasm
6%
Mould
10%
Mycosis
17%
Observational Study
6%
Opportunistic Infection
11%
Pharmacotherapy
7%
Prospective Cohort Study
10%
Psoriasis
6%
Rheumatoid Arthritis
36%
SARS Coronavirus
8%
Sepsis
14%
Systemic Mycosis
23%
Tumor Necrosis Factor
19%
Tumor Necrosis Factor Inhibitor
16%
Vaccination Policy
14%
Varicella Zoster Vaccine
6%
Voriconazole
6%
